Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 111, Issue 6, 2003, Pages 370-373

  Tentolouris, N ^a   Kolia, M ^a   Tselepis, A D ^b   Perea, D ^a   Kitsou, E ^a   Kyriaki, D ^a   Tambaki, A P ^b   Karabina, S P ^b   Sala, C ^c   Fragoulopoulos, E ^c   Katsilambros, N ^a,c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c NONE

Author keywords

Lipoprotein subfractions; Postprandial triglyceridaemia; Repaglinide; Triglycerides; Type 2 diabetes mellitus

Indexed keywords

CHYLOMICRON; FATTY ACID; LIPID; REPAGLINIDE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

ANALYSIS OF VARIANCE; BLOOD GLUCOSE; C-PEPTIDE; CARBAMATES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; PIPERIDINES; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 12444276794     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-42729     Document Type: Article

References (11)

1. Chen YD, Swami S, Skowronski R, Coulston A, Reaven GM. Differences in postprandial lipaemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 76: 172-177
2. Damsbo P, Marbury TC, Hatorp V, Clauson P, Muller PG. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. Diabetes Res Clin Pract 1999; 45: 31 - 39
3. De Man FH, Cabezas MC, Van Barlingen HH, Erkelens DW, de Bruin TW. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 1996; 26: 89-108
4. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM. Diabetologia 1994; 37: 781-787
5. Katsilambros N. Postprandial triglyceridaemia. Diabet Med 1995; 12: 451-452
6. Malaisse WJ. Mechanism of action of new class of insulin secretagogues. Exp Clin Endocrinol Diabetes 1999; 107 (Suppl 4): S140- S143
7. Mohanlal N, Holman RR. The effect of nateglinide stimulated insulin secretion on post challenge glucose and lipid metabolism in type 2 diabetes mellitus. Diabetologia 2002; 45 (Suppl 2): A768
8. Skrapari 1, Perrea D, loannidis 1, Karabina SAP, Elisaf M, Tselepis AD, Karagiannacos P, Katsilambros N. Glibenclimide improves postprandial hypertriglyceridaemia in Type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels. Diabet Med 2001; 18: 781-785
9. Taskinen MR, Beltz WF, Harper I, Fields RM, Schonfeld G, Grundy SM, Howard BV. Effects of NIDDM on very-low-density lipoprotein triglycerides and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy. Diabetes 1986; 35: 1268-1277
10. Taskinen MR. Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes 2001; 109 (Suppl 2): S180-S188
11. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22: 463-467